ArticleMolecular biology reports2025
Inhibitory effects of tetraselmis algae extract on cervical cancer cell proliferation: a molecular and cellular approach.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Synergistic Anti-Lung Cancer Effects of Cytarabine and a NCBI-RegisteredFood science & nutrition · 2026Article
- Probiotic-enhanced chemotherapy: Lactobacillus fermentum synergizes with vincristine to induce apoptosis via dual pathway activation in human cancer cells.Cancer cell international · 2025Article
- Combinational therapy of cervical cancer consisting of probiotic particles and vincristine: a molecular in vitro study.Medical oncology (Northwood, London, England) · 2025Article
- In vitro cytotoxic and pro-apoptotic effects of Chaetoceros socialis ethanolic extract on prostate (LNCap) and glioblastoma (U-87 MG) cells via modulation of AKT/PTEN, mTOR, BAX/BCL2, and Caspase pathways.Medical oncology (Northwood, London, England) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCervical cancer is the leading type of primary malignancy in the uterus, causing significant morbidity and mortality, particularly in developing countries. Traditional treatments often result in severe side effects and recurrence, highlighting the need for safer alternatives. This study investigates the anticancer potential of Tetraselmis suecica, a green microalga known for its bioactive compounds.
methodsHeLa cervical cancer cells and HUVEC were treated with varying concentrations of T. suecica (25, 50, 75, and 100 mg/ml) for 24 h. Cell viability was assessed using the MTT assay, and gene expression related to apoptosis (Bax, Bcl-2, Caspases-3, -8, -9, PTEN, and AKT) was evaluated via real-time PCR for HeLa cells. Apoptosis was quantified using Annexin-V/PI double-staining for HeLa cells as well. The effect on HUVEC cells was assessed only by the MTT assay.
resultsTreatment with T. suecica significantly reduced HeLa cell viability to 25% at 75 mg/ml and increased the expression of pro-apoptotic genes while decreasing anti-apoptotic markers. Apoptotic cell populations rose markedly, indicating that T. suecica induces apoptosis through both intrinsic and extrinsic pathways. However, no significant effect on cell viability or apoptosis was observed in HUVEC cells, suggesting that T. suecica selectively targets cancer cells without affecting normal endothelial cells.
conclusionsT. suecica exhibits promising anticancer properties and may serve as a novel therapeutic agent for cervical cancer, warranting further research into its mechanisms and therapeutic applications. The selective activity on cancer cells and lack of toxicity to normal cells such as HUVECs further supports its potential for targeted cancer therapy.
Indexed as
Identifiers
40397247What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.